RESEARCH ARTICLE

Highlights Regarding Host Predisposing Factors to Recurrent Vulvovaginal Candidiasis: Chronic Stress and Reduced Antioxidant Capacity

Luciene Akimoto-Gunther¹,², Patrícia de Souza Bonfim-Mendonça¹,², Gisele Takahachi², Mary Mayumi T. Irie², Sônia Miyamoto², Márcia Edilaine Lopes Consolaro¹,², Terezinha I. Estivalet Svidzinski¹,²*

¹ Postgraduate Program in Health Sciences, State University of Maringá, Maringá, Brazil, ² Department of Clinical Analyses and Biomedicine, State University of Maringá, Maringá, Brazil

*terezinha.svidzinski@gmail.com

Abstract

We studied host factors that could predispose women to develop recurrent vulvovaginal candidiasis (RVVC), including glycemia, insulin resistance, chronic stress, antioxidant capacity, overall immune status, local inflammation and vaginal microbiota. The presence of yeasts in vaginal culture was screened in 277 women, with or without signs and symptoms of VVC and RVVC. The presence of an inflammatory process and microbiota were analyzed through vaginal bacterioscopy and cervical-vaginal cytology, respectively. Fasting-blood samples were collected by standard venipuncture for biochemical analyses. Flow cytometry was employed to obtain the T helper/T cytotoxic lymphocyte ratio, and insulin resistance was assessed by the HOMA index (HI). Yeasts were isolated from 71 (26%) women: 23 (32.4%) with a positive culture but without symptoms (COL), 22 (31%) in an acute episode (VVC), and 26 (36.6%) with RVVC. \textit{C. albicans} was the main yeast isolated in all clinical profiles. The control group (negative culture) comprised 206 women. Diabetes mellitus and insulin resistance were more associated with the positive-culture groups (COL, VVC and RVVC). The presence of an inflammatory process and microbiota were analyzed through vaginal bacterioscopy and cervical-vaginal cytology, respectively. Fasting-blood samples were collected by standard venipuncture for biochemical analyses. Flow cytometry was employed to obtain the T helper/T cytotoxic lymphocyte ratio, and insulin resistance was assessed by the HOMA index (HI). Yeasts were isolated from 71 (26%) women: 23 (32.4%) with a positive culture but without symptoms (COL), 22 (31%) in an acute episode (VVC), and 26 (36.6%) with RVVC. \textit{C. albicans} was the main yeast isolated in all clinical profiles. The control group (negative culture) comprised 206 women. Diabetes mellitus and insulin resistance were more associated with the positive-culture groups (COL, VVC and RVVC) than with negative ones. The RVVC group showed lower mean levels of cortisol than the control group and lower antioxidant capacity than all other groups. The T Helper/T cytotoxic lymphocyte ratio was similar in all groups. The RVVC group showed a similar level of vaginal inflammation to the control group, and lower than in the COL and VVC groups. Only the CVV group showed a reduction in vaginal lactobacillus microbiota. Our data suggest that both chronic stress (decreased early-morning cortisol levels) and reduced antioxidant capacity can be host predisposing factors to RVVC.
Introduction

Recurrent vulvovaginal candidiasis (RVVC) is a common cause of significant morbidity in women in all strata of society affecting millions of women worldwide [1,2]. Previously RVVC occurrence was limited by onset of menopause but the widespread use of hormone replacement therapy has extended the at-risk period [2]. VVC and RVVC are diseases caused mainly by members of the genus *Candida* [1–3]. These yeasts, in particular *Candida albicans*, are capable of colonizing the human body without producing signs of disease in conditions of physiological equilibrium [1,3]. However, under conditions that disrupt the delicate balance between the host and this commensal fungus, a parasitic relationship may occur, resulting in the development of infections [1–3].

Fungus virulence attributes including adhesion capacity, biofilm development, cell-surface hydrophobicity, morphological transition, and hydrolytic enzymes are related to intrinsic properties of yeasts that increase their ability to cause VVC [4,5]. A recent study showed that the higher prevalence of vaginal candidiasis among diabetics could be related to increased aspartyl proteinases production in this group of patients [6]. In addition to yeasts virulence factors, several host predisposing factors have been suggested [1–3] although few have proved to be involved in the pathogenesis of VVC and particularly RVVC.

The cellular immune response systemic or local and defective neutrophil function may increase susceptibility to infections by *C. albicans*, [7,8] suggesting that clinical conditions such as exposure to chronic stress, diabetes mellitus, or deficient antioxidant micronutrients that alter the proper functioning of the immune system could facilitate RVVC occurrence. Nevertheless, few data are available to help in evaluating the host factors involved in the host-fungus interaction and disease development. In order to further elucidate these relationships, we analyzed intrinsic factors that could predispose women to developing RVVC, including glycemia, insulin resistance, chronic stress, antioxidant capacity, overall immune status, presence of vaginal inflammation, and microbiota.

Materials and Methods

This prospective study included 277 sexually active patients, aged between 18 and 50 years, who were referred to the Clinical Analysis and Research Laboratory of the State University of Maringá (UEM), Paraná, Brazil, from July 1, 2012 to June 30, 2013. The study was carried out with females who visited the laboratory to provide cervical-vaginal samples for clinical analyses, independently of the presence of VVC symptoms. Exclusion criteria were: hysterectomy, pregnant, or in post-partum condition; less than 14 years of age; some degree of difficulty in understanding the study; vaginal bleeding; sexual intercourse/vaginal douching within the 48 hours preceding the collection of the vaginal sample; those who reported receiving antibiotics, corticosteroids or immunosuppressive drugs; and also those with a history of serious debilitating or immunosuppressant disease, including AIDS. All the women or parents gave their written informed consent to participate in the study. This research was approved by the Committee for Ethics in Research with Humans (COEP) of Universidade Estadual de Maringá (UEM) (report no. 435/2009).

After giving their consent, participants were asked to complete an enrollment questionnaire that included detailed questions regarding hypothesized risk factors of VVC (personal/sexual habits, history of VVC diagnoses during lifetime and the past year), presence of VVC signs and symptoms (vaginal discharge, vulvovaginal itching, vulvovaginal burning sensation, dysuria, and dyspareunia), and epidemiological data. Vaginal discharges were appraised by the health professional during sample collection [9].
Vaginal samples were collected with sterile swabs and a disposable vaginal speculum (Vagispec, Santa Catarina, Brazil), inoculated in sterile saline, and immediately seeded onto plates containing Sabouraud dextrose agar (SDA) (Difco, Detroit, Michigan, USA), supplemented with 50 mg/mL chloramphenicol (Sigma Aldrich, St. Louis, Michigan, USA) and incubated at 25°C for up to five days. A pool of the colonies grown on each plate was subcultured on CHROMagar Candida (Probac, Paris, France) to ensure the purity of the isolates and to identify mixed cultures. Beginning with the pure culture, the yeasts were identified by classical phenotypic methods [10]. The yeasts were stored in Sabouraud dextrose broth (SDB) (Difco, Detroit, Michigan, USA) with 10% glycerol at -20°C.

Women with a positive vaginal culture for yeasts were classified based on clinical profiles by physicians in three groups, as follows: 1) colonized (COL)- those without signs and symptoms of VVC; 2) with VVC- those with an acute episode, consisting of women who presented at least two signs or symptoms (discharge, itching, dysuria, and dyspareunia) but no previous episode within a 12-month period; 3) with RVVC- those presenting two or more symptoms in four or more episodes within a 12-month period [9]. Women with a negative vaginal culture were selected as the control group (CG).

A smear was prepared from the vaginal secretion for bacterioscopy. The slides were Gram-stained and examined under an optical microscope at 1.000X magnification. The stained smears were useful to evaluate the presence of yeasts and other infectious agents, vaginal microbiota, and leukocyte reaction. Vaginal microbiota was considered normal when microorganisms morphologically compatible with Lactobacillus spp. were predominant [10].

After sample collection for culture and bacterioscopy, cervical-vaginal samples were obtained from each participant, using an Ayre spatula and a cytobrush, in which triple smears (vaginal, cervical, and endocervical) were prepared and immediately fixed with propylene-glycol spray. The cytological smears were sent to the Clinical Cytology Laboratory (UEM) for analysis. All smears were stained with Papanicolaou (Pap), evaluated in optical microscopy and vaginal inflammation reported according to the Bethesda System/2001 diagnosis criteria by the reference cytologist [11]. The vaginal smears were analyzed for qualitative detection of cellular inflammatory changes in at least 20 different fields under optical microscopy at 400x magnification. The presence of leukocyte and cellular morphological changes in moderate or intense grade were the parameters employed to characterize the inflammation process. The main cellular inflammatory characteristics, as described by Nayar [11], are in the nucleus, that may become compact, dense, and pyknotic, with loss of all chromatin details or degenerated. Such nuclei may have a distinct circumferential cytoplasmic clearing or hollow, causing a perinuclear “halo”. The cytoplasm may show partially or completely disintegrated, amphophilia, and vacuolation [11].

Fasting blood was collected in early morning (07:30 to 09:00 hours) by the standard venipuncture procedure for biochemical measurements. Automated equipment was used to conduct the analyses.

Measurement of plasma glucose was performed by the enzymatic colorimetric glucose-oxidase/GOD-PAP method (DiaSys, Holzheim, Germany), using the Vitalab Selectra 2 system (Elitech Group Solutions, Chicago, Illinois, USA). In this method, glucose is determined after enzymatic oxidation of glucose by glucose oxidase (Trinder reaction). Diabetes was categorized according to the American Diabetes Association (ADA, 2015) [12]. Fasting plasma-glucose levels ≥126 mg/dL or ≥100 and <126 mg/dL, respectively, are used to establish the diagnosis of diabetes and impaired fasting-plasma glucose (decreased glucose tolerance).

Insulin and cortisol levels were determined employing chemiluminescent microparticle immunoassay in the Architect-i1000SR Immunoassay Analyzer (Abbott, Illinois, USA). The cortisol assay has a sensitivity of ≤1 μg/dL and an assay precision of ≤10% total variation.
coefficient (VC) for serum samples. The reference values adopted for fasting cortisol in the mornings were 5.4–25.0 μg/dL or 149–690 nmol/L [12]. The sensitivity of the insulin test is ≤1.0 μU/mL and the precision is ≤7%. The reference values adopted for fasting insulin were 2.5–25.0 μU/mL or 17.9–179.3 pmol/L [12].

Insulin sensitivity was estimated from fasting-glucose and insulin data, using the homeostasis model assessment (HOMA) mathematical model: fasting insulin (μU/mL) + jejum glucose (nmol/L)/22.5 [13]. Insulin resistance was evaluated according to the body mass index (BMI) (1.2±0.65 for BMI <5, 1.8±0.98 for BMI 25–30, and 2.9±1.6 for BMI >30). The BMI was defined by dividing body weight by height squared and used for the classification of excess body weight. The cutoff level of 25 kg/m² suggested by the World Health Organization (WHO) was employed.

Analyses of T cells (T helper/T cytotoxic lymphocyte ratio) were performed on a BD-FACS Calibur flow cytometer equipped with an argon laser and BD Multiset software for data analysis. The reagents employed were BD Multiset CD3/CD4/CD8/CD45 (Becton Dickinson TriT-EST immunofluorescence, Becton Dickinson, San José, California, USA).

The overall antioxidant capacity was determined by Trolox equivalent antioxidant activity (TEAC), which was performed as described by Re et al. [14] to evaluate plasma non-enzymatic antioxidants. This method for screening antioxidant activity is a decolorization assay applicable to both lipophilic and hydrophilic antioxidants, including flavonoids, hydroxycinnamates, carotenoids, and plasma antioxidants. The final results are expressed in micromoles per liter (μM/L). Reference values established for TEAC, considering regional ethnic variations and laboratory conditions, were 1.83–2.07 μM/L.

Data of cortisol levels, overall antioxidant capacity and T Helper/T Cytotoxic lymphocytes are expressed as median [range] with 25th and 75th percentiles. Significant differences among median were analyzed using Prism 6.0 software (GraphPad, San Diego, CA, USA), and identified by the Kruskal-Wallis test with the Dunn’s post hoc test. The Chi-square (χ²) test using the STATA Data Analysis and Statistical Software version 9.1 (Texas, USA) was used to compare values of the control group with the positive-culture group and a crude odds ratio (OR) and 95% confidence interval (CI) were calculated. All variables were expressed as absolute and relative frequencies. P values < .05 were considered significant.

Fig 1 shows a flow chart of the study.

Results

Table 1 shows the epidemiological characteristics of the 277 women (mean age 33.5±8.95 years) included in the study. Women who had two or fewer births and overweight women were significantly more associated with a positive culture for Candida spp. (OR 2.084; 95% CI 0.927–4.685; p = 0.049) and (OR 4.875; 95% CI 1.554–15.285; p = 0.002, respectively).

Vaginal yeasts were isolated in 71 (25.6%) of the 277 women. Women with a negative culture composed the control group (n = 206; mean age 34±10.04 years). With respect to clinical profiles, 23 (32.4%) of the women with a positive culture were classified as COL (mean age 31±8.87 years), 22 (31.0%) as VVC (mean age 35±7.66 years), and 26 (36.6%) as RVVC (mean age 34±9.24 years). The mean ages were similar among women of all clinical profiles (p >0.05). Complete data on the isolation and identification of the yeasts were obtained from all 71 women with a positive culture, as follows: C. albicans (n = 66/71; 93%) and Candida non-C. albicans species (n = 5/71; 7%). C. parapsilosis was the most frequent Candida non-C. albicans species isolated (n = 3/71, 4.2%), followed by C. tropicalis and C. glabrata (n = 1, 1.4% each). C. albicans was the most frequently isolated yeast in all clinical profiles (p = 0.049; Table 2).
The mean values for glycemia were similar in all groups: control (83.40 ±12.47 mg/dL), COL (82±10.45 mg/dL), VVC (89.7±33.61 mg/dL), and RVVC (88.65± 15.9 mg/dL). Abnormal glycemia (≥100 mg/dL) was detected in 16 women (7.8%) of the control group, in 2 (8.7%) of the COL, in 2 (9%) of VVC, and in 3 (11.5%) of RVVC. The HOMA Index (HI) indicating insulin resistance was detected in 42 women (20%) of the control group, in 8 (34.8%) of the COL group, in 4 (18%) of VVC, and in 12 (46%) of RVVC. Compared to the control group, women with a positive culture (COL, VVC and RVVC combined) were associated with an abnormal glucose metabolism (OR 4.6; 95% CI 2.0–10.9; p = 0.0002; Fig 2A) and insulin resistance (OR 2.2; 95% CI 1.05–4.84; p = 0.00317; Fig 2B).

For early-morning cortisol levels, the median (25th-75th percentile) observed were: 17.15 μg/dL (14.00–19.73 μg/dL) in women of the control group, 15.00 μg/dL (13.50–16.00 μg/dL) of the COL group, 13.40 μg/dL (10.88–14.70 μg/dL) of the VVC group, and 10.00 μg/dL (7.55–12.00 μg/dL) of RVVC. Women of the RVVC group showed lower mean cortisol level than the control and COL groups (p< 0.001; Fig 3).
The overall median (25th-75th percentile) levels of antioxidant capacity were: 1.89 mM/L (1.69–2.05 mM/L) in the control group, 1.92 mM/L (1.67–2.10 mM/L) in the COL group, 1.90 mM/L (1.81–2.11 mM/L) in VVC, and 1.52 mM/L (1.39–1.69 mM/L) in RVVC. Women of the

\[ \text{Table 1. Selected epidemiologic characteristics of 277 women who participated of study.} \]

| Characteristics of women | Positive culture group | Control group | OR [95% CI] | p value |
|--------------------------|------------------------|---------------|-------------|---------|
|                          | COL (N = 23) | VVC (N = 22) | RVVC (N = 26) |          |         |
| Age (years)              | n (%)       | n (%)        | n (%)       | n (%)   |          |
| 14–30                    | 12 (52)     | 6 (27)       | 9 (35)      | 81 (39) | 0.702 0.374–1.318 0.269 |
| 31–40                    | 8 (35)      | 10 (46)      | 11 (42)     | 59 (29) | 0.510 0.249–1.046 0.061 |
| >40                      | 3 (13)      | 6 (27)       | 6 (23)      | 66 (32) | 1.0     |
| Deliveries               |             |              |             |          |         |
| None                     | 11 (48)     | 7 (32)       | 10 (38)     | 98 (48) | 2.571 0.831–7.947 0.088 |
| <2                       | 10 (43)     | 14 (64)      | 15 (58)     | 72 (35) | 4.875 1.554–15.285 0.002* |
| >2                       | 2 (9)       | 1 (4)        | 1 (4)       | 36 (17) | 1.0     |
| Menarche (years)         |             |              |             |          |         |
| <12                      | 5 (22)      | 8 (36)       | 11 (42)     | 47 (23) | 1.0     |
| >12                      | 18 (78)     | 14 (64)      | 15 (58)     | 159 (77) | 0.578 0.319–1.048 0.0679 |
| Age first sexual intercourse |             |              |             |          |         |
| Virgin                   | 0 (0)       | 0 (0)        | 0 (0)       | 10 (5) 1.0 |
| <16                      | 10 (43)     | 6 (27)       | 7 (27)      | 57 (28) | 4.035 0.471–34.516 0.167 |
| >16                      | 13 (57)     | 16 (73)      | 19 (73)     | 139 (67) | 3.381 0.416–27.480 0.225 |
| Hormonal Contraception   |             |              |             |          |         |
| No                       | 13 (57)     | 13 (59)      | 14 (54)     | 116 (56) | 1.001 0.580–1.726 0.996 |
| Yes                      | 10 (43)     | 9 (41)       | 12 (46)     | 90 (44) | 1.0     |
| Number of sexual partners (last year) |             |              |             |          |         |
| None                     | 2 (9)       | 1 (5)        | 1 (4)       | 27 (13) | 1.065 0.210–5.403 0.938 |
| >1                       | 19 (82)     | 20 (90)      | 25 (96)     | 162 (79) | 0.394 0.111–1.391 0.134 |
| >2                       | 2 (9)       | 1 (5)        | 0 (0)       | 17 (8) 1.0 |
| BMI                      |             |              |             |          |         |
| 18–24                    | 13 (56)     | 13 (59)      | 11 (42)     | 182 (88) | 1.010 0.441–2.311 0.980 |
| 25–29                    | 8 (35)      | 8 (36)       | 9 (35)      | 16 (8) 2.084 0.927–4.685 0.049* |
| >30                      | 2 (9)       | 1 (5)        | 6 (23)      | 8 (4) 1.0 |

COL, vaginal colonization; VVC, vulvovaginal candidiasis; RVVC, recurrent vulvovaginal candidiasis; BMI, body mass index; OR, Odds Ratio; 95% CI, confidence interval. *p<0.05 was considered significant

doi:10.1371/journal.pone.0158870.t001

The overall median (25th-75th percentile) levels of antioxidant capacity were: 1.89 mM/L (1.69–2.05 mM/L) in the control group, 1.92 mM/L (1.67–2.10 mM/L) in the COL group, 1.90 mM/L (1.81–2.11 mM/L) in VVC, and 1.52 mM/L (1.39–1.69 mM/L) in RVVC. Women of the

\[ \text{Table 2. Relative distribution of Candida albicans and Candida non-C. albicans species according to the clinical profile.} \]

| Species            | Total (N = 71) | COL (N = 23) | VVC (N = 22) | RVVC (N = 26) | p value |
|--------------------|----------------|--------------|--------------|---------------|---------|
|                    | n (%)          | n (%)        | n (%)        | n (%)         |         |
| C. albicans        | 66 (93)        | 19 (82.7)    | 21 (95.5)    | 26 (100)      | 0.049*  |
| CNCA               |                |              |              |               |         |
| C. parapsilosis    | 5 (3)          | 4 (2)        | 1 (4.3)      | -             | -       |
| C. glabrata        | 1 (20)         | 1 (4.3)      | -            | -             | -       |
| C. tropicalis      | 1 (20)         | 1 (4.3)      | -            | -             | -       |
| Total              | 71 (100)       | 23 (100)     | 22 (100)     | 26 (100)      |         |

COL, vaginal colonization; VVC, vulvovaginal candidiasis; RVVC, recurrent vulvovaginal candidiasis. CNCA, Candida non-C. albicans. *p<0.05 was considered significant

doi:10.1371/journal.pone.0158870.t002
Fig 2. Abnormal glycemia and insulin resistance in 277 women studied. **A.** Percentage of women with abnormal glycemia (≥126 mg/dL) in control group compared to positive vaginal yeast culture group (colonized-COL, vulvovaginal candidiasis-VVC and recurrent VVC-RVVC). Positive culture group had more women with abnormal glycemia than control group (*p = 0.0002). **B.** Percentage of women with insulin resistance (HOMA Index ≥ reference value according to body mass index-BMI) in positive vaginal culture.
RVVC group had a significantly lower overall median level of antioxidant capacity than the control group ($p<0.0001$), the COL group ($p<0.0001$), and also VVC ($p<0.0001$; Fig 4).

The median (25th–75th percentile) T helper/T cytotoxic lymphocyte ratios were: 1.95 (1.79–2.25) in the control group, 1.41 (1.33–1.56) in COL, 1.50 (1.21–1.71) in VVC; and 1.71 (1.46–1.79) in RVVC. The COL, VVC and RVVC group had lower T helper/T cytotoxic lymphocyte ratios than the control group ($p<0.0001$ for all; Fig 5).

Cytology of Pap showed a similar vaginal inflammatory process in women of the RVVC and control groups (OR 1.96; 95% CI 0.83–3.87; $p=0.188$) while women of the VVC and COL groups showed a more-intense inflammatory process than the control group (OR 9.47; 95% CI 4.03–16.44; $p=0.0001$) and (OR 5.22; 95% CI 1.97–8.69; $p=0.0003$; Fig 6A).

Bacterioscopy showed that women in the COL and RVVC groups had similar normal Lactobacillus spp. vaginal microbiota to the control group (OR 1.429; 95% CI 0.593–3.44; $P=0.5223$) and (OR 0.5896; 95% CI 0.2346–1.482; $p=0.2815$, respectively). Women of the VVC group compared to control group. Positive culture group had more women with insulin resistance than control group ($*p=0.0002$).

**Fig 3.** Morning cortisol levels according to the women clinical profiles. Median values of each group (Control, COL, VVC and RVVC) were calculated and compared using a Kruskal-Wallis and subsequently Dunn’s post-hoc test with all pairwise comparisons identified which groups differed. Box plots show the median, 25th and 75th percentiles of the cortisol levels. Whiskers extend to the 5th and 95th percentiles; filled circles represent outliers. Cortisol levels were determined in triplicate employing chemiluminescent microparticle immunoassay in the Architect-i1000SR Immunoassay Analyzer (Abbott, Illinois, USA). *$p=0.001$, shows that women of the RVVC group has a lower mean cortisol level than the control and COL groups.

**Fig 4.** Median values of antioxidant capacity (GSH-Px activity, U/mg of protein) of the RVVC, control, COL and VVC groups. The RVVC group had a significantly lower overall median level of antioxidant capacity than the control group ($p<0.0001$), the COL group ($p<0.0001$), and also VVC ($p<0.0001$; Fig 4).
showed fewer vaginal lactobacilli compared to women of the COL and RVVC groups (OR 2.914; 95% IC 0.8634–9.836; \( p = 0.0404 \), and OR 2.712; 95% CI 0.8275–8.810; \( p = 0.0480 \), respectively; Fig 6B).

Discussion

In this study, the early-morning cortisol level and overall antioxidant capacity were lower in women with RVVC than in women of the control and COL groups. This suggests that chronic stress and reduced antioxidant capacity may be specific predisposing factors related to the pathogenesis of RVVC. In addition, other factors such as diabetes mellitus and insulin resistance were related to positive vaginal yeast culture but not related to a specific clinical profile (COL, VVC and RVVC). These data support our hypothesis concerning the importance of chronic stress and reduced antioxidant capacity as specific predisposing factors for the development of RVVC.

Attenuated levels of morning cortisol and hyporesponsiveness of the hypothalamus–pituitary–adrenal axis have been shown to be indicative of chronic stress [13–15]. Also, stress may increase the risk for impaired function of the immune processes [16]. Clinical observations and
experimental findings have further emphasized the role of chronic stress as an important triggering factor of many pathologies including atopic dermatitis, systemic lupus erythematosus, asthma, allergic rhinitis and Candida infections [13–17]. These studies are in agreement with our results, which indicated a relationship between chronic stress and vulvovaginal candidiasis (RVVC and VVC). Despite these results being in line with earlier findings that correlate lower levels of early-morning cortisol with RVVC [17, 18], it is possible that stress may be a predisposing factor for RVVC as well as a response to repeated infections.

A reduced overall antioxidant capacity has also been associated with immune deficiency, since its mechanism of action seems to be the modulation of signal transduction factors involving transcribing cells and immune-mediated cytokine production [19,20]. Additionally, it is important to consider that the elimination of Candida is a cell-mediated immune responses by the recruitment and activation of neutrophils, which respond to a proinflammatory cytokine [19–21]. The reduced overall antioxidant capacity, and the altered immune status in the RVVC group compared to all other groups, suggest that impaired immunity plays a role in the pathogenesis of RVVC.
Health benefits have also been attributed to antioxidants, including a reduced risk of coronary vascular diseases and some types of cancer [22]. In their etiology, these chronic diseases seem to result from cellular oxidative damage, caused by pro-oxidative agents such as free radicals, affecting lipids, proteins and DNA [7,8]. Dietary antioxidants may protect against these oxidative events in the body in cases where insufficient levels of endogenous antioxidants cannot counteract the reactive species [22]. It is possible that an increase in antioxidant defense provided by dietary vitamins and minerals may prevent RVVC.

In this study, we assessed the immune status by determining the lymphocyte T helper/T cytotoxic ratio in blood. Our results showed that women with RVVC had reduction in systemic cell-mediated immunity (CMI) responsiveness and the cytological findings indicated that women with RVVC had a lower local inflammatory response than the women in other groups with a positive culture (Fig 6). These data are in accordance with the findings of Fidel et al. [23] who showed that a local rather than a systemic CMI represents important host-defense mechanisms in the vaginal mucosa. Thereby, additional efforts and studies with the local T-cell count, besides other strategies such as interleukin genotyping, will be needed to assess the CMI responsiveness of patients with RVVC.

Diabetes mellitus has long been considered as one of the factors causing Candida vaginitis, mainly due to the changes induced by hyperglycemia, including decreased random motion of neutrophils, chemotaxis, phagocytosis, and microbial death [24–26]. High blood glucose levels promote yeast attachment and growth, and also interfere with immune responses in the host [27]. However, in many cases there is a lack of reliable and clinically relevant information proving diabetes mellitus as a risk factor to RVVC [28]. We recently showed that diabetes mellitus type 2 in Brazilian women was associated with vaginal yeast colonization, VVC and RVVC [29]. Donders et al [26] found impaired glucose tolerance in women with RVVC, compared to controls. However, we found no relationship between RVVC and diabetes mellitus. One hypothesis that partly explains this is that the increased glucose at the vaginal level could be more than hyperglycemia in the pathogenesis of RVVC, because it would increase the adhesion and growth of yeasts as previously showed [26]. Still, Nyirjesy et al. [24] proposed that women with type 2 diabetes mellitus are at increased risk for vaginal Candida colonization because of glucosuria, which may also to justify our results. However, as we did not evaluate the vaginal and urinary glucose levels, additional studies are needed to examine such hypothesis.

The findings of studies on the impact of vaginal lactobacilair microbiota on the control of VVC and RVVC are contradictory [30,31]. Our results suggest that the vaginal communities of women with RVVC did not have reduced proportions of lactobacilli. These findings are consistent with others that also showed, using culture-dependent methods, that the development of RVVC was not correlated with an abnormal vaginal microbiota [31].
Finally, we are making a substantial assumption that both chronic stress (decreased early-morning cortisol levels) and decreased overall antioxidant capacity are present in women with RVVC. In addition, we have considered these data as host predisposing factors for developing recurrent status. In fact, our findings provided important information to better understand this pathology and lead to improved care for women with RVVC. However, this speculation was made based in a cross-sectional study, and this kind of design implies a limitation regarding to statements made. Despite these data alone are unable to reach results that would qualify as definitive, they supply a strong possibility. For a definitive conclusion, a longitudinal study, where women’s cortisol levels be tested during an infection process, following the treatment, and in periods of remission, must be carried on.

**Financial disclosure:** The authors did not report any potential conflict of interest.

**Author Contributions**

Conceived and designed the experiments: LAG PSBM MELC. Performed the experiments: PSBM GT SM MMTI. Analyzed the data: MELC LAG PSBM TIES. Contributed reagents/materials/analysis tools: MELC TIES LAG. Wrote the paper: TIES MELC PSBM LAG.

**References**

1. Cassone A. Vulvovaginal *Candida albicans* infections: pathogenesis, immunity and vaccine prospects. BJOG 2015; 122:785–94. doi: 10.1111/1471-0528.12994 PMID: 25052208

2. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2015; 15:716–24.

3. Sobel JD. Vulvovaginal candidiosis. Lancet 2007; 369:1961–71. PMID: 17560449

4. Sandini S, La Valle R, Deaglio S, Malavasi F, Cassone A, De Bernardis F. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of *Candida albicans* as a mucosal anticandidal vaccine. FEMS Immunol Med Microbiol 2011; 62:215–24. doi: 10.1111/j.1574-695X.2011.00802.x PMID: 21535228

5. Muzny CA, Schwebke JR. Biofilms: an underappreciated mechanism of treatment failure and recurrence in vaginal infections. Clin Infect Dis 2015; 61:601–6. doi: 10.1093/cid/civ353 PMID: 25935553

6. Bassseyouni RH, Wegdan AA, Abdelmonem A, Said W, AboElnaga F. Phospholipase and aspartyl proteinase activities of *Candida* species causing vulvovaginal candidiasis in patients with type 2 diabetes mellitus. J Microbiol Biotechnol 2015; 25:01–22.

7. Ratti BA, Godoy JS, de Souza Bonfim-Mendonça P, Bidóia DL, Nakamura TU, Nakamura CV, et al. Microbicidal activity of neutrophils is inhibited by isolates from recurrent vaginal candidiasis(RVVC) caused by *Candida albicans* through fungal thioredoxin reductase. Cell Immunol 2015; 293:22–9. doi: 10.1016/j.cellimm.2014.11.004 PMID: 25497972

8. Bonfim-Mendonça PS, Ratti BA, Godoy JS, Negri M, Lima NC, Fiorini A, et al. β-glucan induces reactive oxygen species production in human neutrophils to improve the killing of *Candida albicans* and *Candida glabrata* isolates from vulvovaginal candidiasis. Plos One 2014; 9:e107805. doi: 10.1371/journal.pone.0107805 PMID: 25229476

9. Odds FC, Webster CE, Mayuranathan P, Simmons PD. *Candida* concentrations in the vagina and their association with signs and symptoms of vaginal candidosis. J Med Vet Mycol 1988; 26: 277–83. PMID: 3236147

10. Kurtzman CP, Fell JW. The yeast, a taxonomic study. New York (NY): Elsevier; 1998.

11. Nayar R, Wilbur CD. The Bethesda System for reporting cervical cytology: definitions, criteria and explanatory notes. Cham (Switzerland): Springer International Publishing; 2015.

12. American Diabetes Association (ADA). Standards of medical care in diabetes-2015: summary of revisions. Diabetes Care 2015; 38(suppl 1):S4.

13. Wallace TM, Levy JC, Mathews DR. Use and abuse of HOMA modeling. Diab Care 2004; 27:1487–95.

14. Re R, Pellegrini R, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Rad Biol Med 1999; 26:1231–7. PMID: 10381194

15. Jönsson P, Österberg K, Wallergård M, Hansen ÅM, Garde AH, Johansson G, Karlson B. Exhaustion-related changes in cardiovascular and cortisol reactivity to acute psychosocial stress. Physiol Behav 2015; 15:30034–2.
16. Straub RH. Neuroendocrine immunology: new pathogenetic aspects and clinical application. Z Rheumatol 2011; 70:767–74. doi: 10.1007/s00393-011-0784-8 PMID: 21956825

17. Ehrstrom SM, Kornfeld D, Thurersson J, Rylander E. Signs of chronic stress in women with recurrent candida vulvovaginitis. Am J Obstet Gynecol 2005; 4:1376–81.

18. Meyer H, Goettlicher S, Mendling W. Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antifungal therapy. Mycoses 2006; 49:202–9. PMID: 16681811

19. Richardson M, Rautemaa R. How the host fights against Candida infections. Front Biosci 2009; 14:4363–75.

20. Fidel PL Jr. History and update on host defense against vaginal candidiasis. Am J Reprod Immunol 2007; 57:2–12. PMID: 17156186

21. Amouri I, Hadrich I, Abbes S, Sellami H, Ayadi A. Local humoral immunity in vulvovaginal candidiasis. Ann Biol Clin 2013; 71:151–5.

22. Smith RA, Adlam VJ, Blakie FH, Manas AR, James AM, et al. Mitochondria-targeted antioxidants in the treatment of disease. Ann N Y Acad Sci 2008; 1147:105–11. doi: 10.1196/annals.1427.003 PMID: 19076435

23. Fidel PLJ, Lynch ME and Sobel JD. Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect Immun 1995; 63:2403–8. PMID: 7790050

24. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28:1173–8. doi: 10.1185/03007995.2012.697053 PMID: 22632452

25. Carrara MA, Bazotte RB, Donatti L, Svidzinski TI, Consolaro ME, Patussi EV, et al. Effect of experimental diabetes on the development and maintenance of vulvovaginal candidiasis in female rats. Am J Obstet Gynecol 2009; 200:659.e1-4.

26. Donders GG, Prenen H, Verbeke G, Reybrouck R. Impaired tolerance for glucose in women with recurrent vaginal candidiasis. Am J Obstet Gynecol 2002; 187:989–93. PMID: 12388993

27. Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med 2013; 125:33–46. doi: 10.3810/pgm.2013.05.2650 PMID: 23748505

28. Buchta V, Matula V, Kestřánek J, Vejsová M, Křivčíková L, Špaček J. Is diabetes mellitus a risk factor in genital yeast infections?. Ceska Gynekol 2013; 78:537–44. PMID: 24372432

29. Gunther LS, Martins HP, Gimenes F, Abreu AL, Consolaro ME, Svidzinski TI. Prevalence of Candida albicans and non-albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non-diabetic women. Sáo Paulo Med J 2014; 132:116–20. PMID: 24714993

30. Liu M, Xu S-R, He Y, Deng G-H, Sheng H-F, Huang XM, et al. Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. Plos One 2013; 8:e79812. doi: 10.1371/journal.pone.0079812 PMID: 24265786

31. Zhou X, Westman R, Hickey R, Hansmann MA, Kennedy C, Osborn TW, et al. Vaginal microbiota of women with frequent vulvovaginal candidiasis. Infect Immun. 2009; 77:4130–5. doi: 10.1128/IAI.00436-09 PMID: 19528218